AbbVie Inc. has obtained a supplemental US approval for atypical antipsychotic Vraylar (cariprazine) that the company and at least one analyst believe could add a billion-dollar opportunity to the drug’s existing label. The Chicago pharma revealed late on 16 December that the US Food and Drug Administration approved Vraylar as an adjunctive treatment for major depressive disorder in adults.
AbbVie’s Blockbuster Vraylar Adds Significant Indication, Adjunctive MDD
Already selling at a run rate above $2bn annually, AbbVie predicts the atypical antipsychotic could reach the $4bn mark with a new US indication for adjunctive treatment of major depressive disorder.
More from New Products
More from Scrip
• By
The US president's most recent comments suggest tariffs on pharma are imminent and Ireland has the most to lose.
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.